Conatus Pharmaceuticals (CNAT) Earning Somewhat Favorable News Coverage, Analysis Finds

News coverage about Conatus Pharmaceuticals (NASDAQ:CNAT) has trended somewhat positive recently, according to Accern Sentiment. The research group identifies negative and positive news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Conatus Pharmaceuticals earned a news impact score of 0.16 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 46.4325816066513 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

These are some of the news headlines that may have impacted Accern Sentiment’s rankings:

Shares of NASDAQ:CNAT traded up $0.12 during midday trading on Friday, reaching $5.42. The company had a trading volume of 830,027 shares, compared to its average volume of 678,924. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.41 and a current ratio of 2.41. The company has a market cap of $162.94 million, a P/E ratio of -8.89 and a beta of 1.29. Conatus Pharmaceuticals has a 1-year low of $3.22 and a 1-year high of $7.95.

Conatus Pharmaceuticals (NASDAQ:CNAT) last released its earnings results on Wednesday, May 2nd. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.17). The business had revenue of $9.74 million for the quarter, compared to the consensus estimate of $8.88 million. Conatus Pharmaceuticals had a negative return on equity of 64.30% and a negative net margin of 49.30%. equities analysts predict that Conatus Pharmaceuticals will post -0.68 earnings per share for the current fiscal year.

Several analysts have issued reports on CNAT shares. Zacks Investment Research raised Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, February 27th. ValuEngine raised Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, March 2nd. SunTrust Banks lowered their target price on Conatus Pharmaceuticals to $4.30 and set a “buy” rating on the stock in a research report on Thursday, April 5th. HC Wainwright lowered their target price on Conatus Pharmaceuticals from $17.00 to $15.00 and set a “buy” rating on the stock in a research report on Thursday, April 5th. Finally, Oppenheimer assumed coverage on Conatus Pharmaceuticals in a research report on Thursday, March 1st. They issued a “buy” rating and a $16.00 target price on the stock. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Conatus Pharmaceuticals has an average rating of “Buy” and a consensus target price of $12.14.

Conatus Pharmaceuticals Company Profile

Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.

Insider Buying and Selling by Quarter for Conatus Pharmaceuticals (NASDAQ:CNAT)

Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply